Stock DTC DEFENCE THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Defence Therapeutics Inc.

Equities

DTC

CA24463V1013

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange
Other stock markets
 15:59:00 2024-05-03 EDT 		5-day change 1st Jan Change
1.47 CAD -9.26% Intraday chart for Defence Therapeutics Inc. +17.60% -36.91%
03-26 Defence Therapeutics Inc. Announces the Successful Testing of Second-Generation Anti-Cancer Vaccine, Called ARM-002TM CI
03-01 Defence Therapeutics Inc. Announces Peer-Reviewed Publication on Accum-E7 Anti-Cancer Vaccine in Cancer Science Journal and Financing Update CI

Valuation

Fiscal Period: June 2021 2022 2023
Capitalization 1 245.3 73.23 127.5
Enterprise Value (EV) 1 239.9 72.72 126.5
P/E ratio -65.6 x -9.83 x -17.1 x
Yield - - -
Capitalization / Revenue - - -
EV / Revenue - - -
EV / EBITDA - - -19,519,801 x
EV / FCF -200,500,528 x -22,400,014 x -23,681,510 x
FCF Yield -0% -0% -0%
Price to Book 45.3 x -189 x 81.6 x
Nbr of stocks (in thousands) 34,801 36,615 43,681
Reference price 2 7.050 2.000 2.920
Announcement Date 21-10-27 22-10-24 23-10-27
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2019 2020 2021 2022 2023
Net sales - - - - -
EBITDA - - - - -6.481
EBIT 1 -0.0419 -0.6732 -2.826 -7.274 -6.494
Operating Margin - - - - -
Earnings before Tax (EBT) 1 -0.001946 -0.6732 -2.859 -7.344 -6.868
Net income 1 -0.001946 -0.6732 -2.859 -7.344 -6.763
Net margin - - - - -
EPS - -0.7137 -0.1075 -0.2036 -0.1705
Free Cash Flow - -0.2393 -1.196 -3.247 -5.342
FCF margin - - - - -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 21-02-02 21-02-02 21-10-27 22-10-24 23-10-27
1CAD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: Juni 2019 2020 2021 2022 2023
Net Debt 1 - - - - -
Net Cash position 1 0 1.87 5.45 0.51 1.05
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow - -0.24 -1.2 -3.25 -5.34
ROE (net income / shareholders' equity) - -72.2% -77.8% -288% -1,148%
ROA (Net income/ Total Assets) - -43.8% -47% -144% -191%
Assets 1 - 1.536 6.088 5.112 3.542
Book Value Per Share - 0.1000 0.1600 -0.0100 0.0400
Cash Flow per Share - 0.1000 0.1500 0.0100 0.0600
Capex - - - - 0.07
Capex / Sales - - - - -
Announcement Date 21-02-02 21-02-02 21-10-27 22-10-24 23-10-27
1CAD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
DEFENCE THERAPEUTICS INC. Stock Defence Therapeutics Inc.
-36.91% 48.81M
MODERNA, INC. Stock Moderna, Inc.
+25.69% 47.86B
LONZA GROUP AG Stock Lonza Group AG
+46.90% 41.42B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.46% 40.66B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.92B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+9.17% 25.55B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.42% 19.27B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.17% 12.15B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.07% 12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.24% 11.99B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. DTC Stock
  4. Financials Defence Therapeutics Inc.